Display Settings:

Format

Send to:

Choose Destination

    Antimicrob Agents Chemother. 2006 Jun;50(6):2207-9.

    Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.

    Parikh S, Liu J, Sijwali P, Gut J, Goldberg DE, Rosenthal PJ.

    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, 94110, USA. sparikh@medsfgh.ucsf.edu

    Human immunodeficiency virus type 1 protease inhibitors (HIVPIs) and pepstatin are aspartic protease inhibitors with antimalarial activity. In contrast to pepstatin, HIVPIs were not synergistic with a cysteine protease inhibitor or more active against parasites with the cysteine protease falcipain-2 knocked out than against wild-type parasites. As with pepstatin, HIVPIs were equally active against wild-type parasites and against parasites with the food vacuole plasmepsin aspartic proteases knocked out. The antimalarial mechanism of HIVPIs differs from that of pepstatin.

    PMID: 16723585 [PubMed - indexed for MEDLINE]

    PMCID: 1479139

    Supplemental Content

    Click here to read Click here to read